Biofrontera Inc
$ 0.85
-1.75%
24 Feb - close price
- Market Cap 10,072,300 USD
- Current Price $ 0.85
- High / Low $ 0.85 / 0.81
- Stock P/E N/A
- Book Value -0.22
- EPS -1.50
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.65 %
- ROE -11.92 %
- 52 Week High 1.19
- 52 Week Low 0.54
About
Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
Analyst Target Price
$6.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-13 | 2025-05-13 | 2025-03-13 | 2024-11-13 | 2024-08-14 | 2024-05-15 | 2024-03-15 | 2023-11-09 | 2023-08-11 | 2023-05-12 | 2023-03-08 |
| Reported EPS | -0.62 | -0.57 | -0.5084 | -0.232 | -0.8138 | -0.05 | -2.88 | 1.65 | -4.64 | -7.23 | -0.28 | -0.14 |
| Estimated EPS | -0.57 | -0.57 | -0.29 | -0.07 | -0.83 | -0.77 | -1.17 | -1.19 | -3.78 | -4.61 | -0.19 | -0.11 |
| Surprise | -0.05 | 0 | -0.2184 | -0.162 | 0.0162 | 0.72 | -1.71 | 2.84 | -0.86 | -2.62 | -0.09 | -0.03 |
| Surprise Percentage | -8.7719% | 0% | -75.3103% | -231.4286% | 1.9518% | 93.5065% | -146.1538% | 238.6555% | -22.7513% | -56.833% | -47.3684% | -27.2727% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.29 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BFRI
2026-02-19 03:13:43
Biofrontera (NASDAQ:BFRI) is identified as a superior biotech stock compared to RenovaCare (OTCMKTS:RCAR) based on analyst recommendations, valuation, earnings, and institutional ownership. Analysts project a potential upside of 252.56% for Biofrontera, which also boasts higher revenue and stronger institutional backing. While RenovaCare has higher earnings per share, its stock exhibits greater volatility.
2026-02-17 19:13:30
Biofrontera Inc. (NASDAQ: BFRI) has completed the database lock for its Phase I pharmacokinetic study of Ameluz® for actinic keratosis on the trunk and extremities. This milestone signifies the end of data collection for the clinical trial, paving the way for subsequent analysis and evaluation of results. The company anticipates that this study will further enhance the clinical data available for Ameluz® in dermatological disease treatment.
2026-02-17 14:27:47
Biofrontera Inc. (NASDAQ: BFRI) has completed the database lock for its Phase I pharmacokinetic study of Ameluz® for actinic keratosis on the trunk and extremities. This significant milestone marks the official conclusion of data collection, preparing the ground for subsequent analysis and evaluation. The company anticipates this study will expand the clinical data for Ameluz® in dermatological treatment.
2026-02-17 14:27:47
Biofrontera Inc. announced the database lock for its Phase 1 pharmacokinetics (PK) study of Ameluz gel for treating actinic keratoses on the neck, trunk, and extremities. This study, which measured plasma ALA and PpIX after one PDT treatment in 17 patients, is a crucial step towards submitting a supplemental New Drug Application (sNDA) in Q3 2026. If approved, the sNDA will expand Ameluz's U.S. label to cover treatment fields up to 240 cm², significantly increasing its utility beyond the current 60 cm² for face and scalp.
2026-02-17 14:15:00
Biofrontera Inc. announced the database lock for its Phase 1 pharmacokinetics (PK) study of Ameluz® for treating actinic keratoses (AKs) on the neck, trunk, and extremities. This study, completed on February 11, 2026, assessed systemic exposure to ALA and PpIX during photodynamic therapy with Ameluz® and the BF-RhodoLED® XL lamp. The data, combined with positive Phase 3 results, will support a supplemental New Drug Application (sNDA) to the FDA in Q3 2026, aiming to expand Ameluz®’s label to treat larger AK fields on additional body areas.
2026-02-17 05:21:56
Biofrontera Inc. (NASDAQ: BFRI) has completed the database lock for its Phase I pharmacokinetic study of Ameluz® for actinic keratosis on the trunk and extremities. This significant milestone marks the end of data collection for the clinical trial, paving the way for detailed analysis and evaluation of the results. The company anticipates that this advancement will broaden the clinical understanding and application of Ameluz® in dermatology.
